Currently, we are investigating the presence of AQP5 mutation with the CML samples, especially with the paired samples drawn before and after the emergence of imatinib mesylate resistance in the same CML patients. The gene discussed is AQP5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.